Sildenafil
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist.
MenUp contains the active substance sildenafil, which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. The medicine works by helping to relax the blood vessels in the penis, increasing blood flow to the penis during sexual stimulation. MenUp helps achieve an erection only if there is prior sexual stimulation. MenUp is used to treat erectile dysfunction in adult men, which is the inability to achieve or maintain an erection sufficient for sexual intercourse.
Before starting to take MenUp, the patient should discuss this with their doctor or pharmacist in the following cases:
MenUp should not be taken with other oral or locally applied erectile dysfunction therapies. MenUp should not be taken with pulmonary arterial hypertension therapies that use sildenafil or other PDE5 inhibitors. MenUp should not be taken if erectile dysfunction has not been diagnosed. MenUp is not intended for women. Special considerations for patients with kidney or liver function disordersPatients with kidney or liver function disorders should inform their doctor. Patients with kidney or liver function disorders should not take a dose of MenUp higher than 25 mg.
MenUp should not be taken by persons under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. MenUp may interact with some medicines, especially those used to treat chest pain. If the patient's condition worsens, requiring immediate medical attention, they should inform their doctor, pharmacist, or nurse about taking MenUp and the time of taking it. MenUp should not be taken with other medicines without the doctor's recommendation. MenUp should not be taken if the patient is taking nitrate medicines, as their concurrent use may lead to a dangerous decrease in blood pressure. The patient should always inform their doctor or pharmacist if they are taking nitrates, which are used to treat angina pectoris (chest pain). MenUp should not be taken if the patient is taking medicines that release nitric oxide (such as amyl nitrite), as their concurrent use may also cause a dangerous decrease in blood pressure. If the patient is already taking riociguat, they should inform their doctor or pharmacist. When taking protease inhibitors used to treat HIV infections, it is recommended to start treatment with the lowest dose (25 mg) of MenUp. In some patients who take alpha-adrenergic blockers for high blood pressure or prostate enlargement, dizziness or lightheadedness may occur, which can be symptoms of low blood pressure caused by a drop in blood pressure when standing up or sitting down quickly. Such symptoms occurred in some patients taking MenUp and alpha-adrenergic blockers. Their occurrence is most likely within 4 hours of taking MenUp. To reduce the possibility of these symptoms, the patient should regularly take their fixed dose of alpha-adrenergic blocker before starting MenUp. The doctor may decide to use a lower initial dose (25 mg) of MenUp. If symptoms of low blood pressure (dizziness, lightheadedness, feeling of impending faint) occur, the patient should first lie down or sit and wait for the symptoms to pass; drinking water, taking fresh air, tensing abdominal muscles, or crossing legs may also help. The patient should avoid standing up or sitting down quickly. If the patient is taking medicines containing sacubitril with valsartan (used to treat heart failure), they should inform their doctor or pharmacist.
MenUp can be taken with or without food. Although taking MenUp during a heavy meal may prolong the time needed for the medicine to start working. The ability to achieve an erection may be temporarily impaired after consuming alcohol. To maximize the therapeutic benefits of MenUp, the patient should not consume large amounts of alcohol before taking the medicine.
MenUp is not intended for use by women.
MenUp may cause dizziness and vision disturbances. Patients should be aware of how they react to MenUp before driving or operating machinery.
If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking MenUp. The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist. The recommended dose of MenUp is 25 mg. The doctor may recommend a different dosing regimen after consultation. MenUp should not be taken more than once a day.MenUp film-coated tablets should not be taken at the same time as Viagra tablets or other medicines containing sildenafil. MenUp should be taken about an hour before planned sexual activity. The tablet should be swallowed whole, with a glass of water. If the patient feels that the effect of MenUp is too strong or too weak, they should consult their doctor or pharmacist. MenUp allows for an erection only if there is prior sexual stimulation. The time it takes for MenUp to work varies from person to person, usually between half an hour and one hour. The effect may occur later if MenUp is taken after a heavy meal. The patient should contact their doctor if, after taking MenUp, they do not achieve an erection or if the duration of the erection is not sufficient for sexual intercourse.
The patient may experience more frequent side effects, and they may be more severe. Taking a dose higher than 100 mg does not increase the effectiveness of the medicine. The patient should not take more tablets than indicated in the patient leaflet.The patient should contact their doctor in case of taking more tablets than recommended. If the patient has any further doubts about the use of this medicine, they should consult their doctor or pharmacist.
Like all medicines, MenUp can cause side effects, although not everybody gets them. Side effects reported in connection with the use of MenUp are usually mild or moderate and short-lived.
Common(may occur in up to 1 in 10 patients) :
Uncommon(may occur in up to 1 in 100 patients) :
Rare(may occur in up to 1 in 1000 patients) :
After the introduction of sildenafil-containing medicines to the market, rare cases of unstable angina (heart disease) and sudden death have been reported. It is important to note that in most, but not all, men who experienced these side effects, heart function disorders occurred before taking the sildenafil-containing medicine. It is not possible to determine whether these side effects were related to the use of MenUp.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Post-Marketing Surveillance of Medicinal Products, Medical Devices, and Biocidal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C PL-02 222 Warsaw Tel.: + 48 22 49 21 301 Fax: + 48 22 49 21 309 Website: https://smz.ezdrowie.gov.pl Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. There are no special precautions for storing the medicine. Do not use this medicine after the expiry date stated on the blister pack and carton after EXP:. The expiry date refers to the last day of the month. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
OPADRY II 32K205007 blue coating: hypromellose 15 mPa⸳s, lactose monohydrate, titanium dioxide (E 171), triacetin, indigo carmine (E 132), aluminum lake.
MenUp film-coated tablets are blue, round, 7 mm in diameter, biconvex, with the number "25" on one side. PVC/PVDC/Aluminum blisters in a carton box containing 2, 4, or 8 tablets. Not all pack sizes may be marketed.
Silesian Pharma Sp. z o.o. ul. Szopienicka 77 40-431 Katowice tel: (32) 20 80 600
Adamed Pharma S.A. ul. Marszałka J. Piłsudskiego 5 95-200 Pabianice
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.